Peripheral T-cell Lymphoma in Japan: Real-World Patient Characteristics, Treatment Patterns, Healthcare Resource...

Area of Science:

• Oncology
• Hematology
• Health Economics

Background:

• Peripheral T-cell lymphomas (PTCLs) are aggressive non-Hodgkin lymphomas with poor outcomes.
• PTCL represents a larger fraction of non-Hodgkin lymphoma cases in Japan than in Western countries.
• Limited real-world data exists on PTCL treatment patterns, healthcare resource utilization (HRU), and costs in Japan.

Purpose of the Study:

• To describe real-world patient characteristics in Japan.
• To analyze treatment patterns for PTCL in Japan.
• To evaluate healthcare resource utilization (HRU) and associated costs for PTCL patients in Japan.

Main Methods:

• Retrospective observational study using Japanese administrative claims data (Medical Data Vision).
• Included adult patients diagnosed with PTCL between September 2012 and August 2022.
• Analyzed demographics, comorbidities, treatment regimens, time on treatment, HRU, and costs per patient per month.

Main Results:

• 910 patients identified; 71.3% received systemic therapy.
• Mean age at diagnosis was 69.8 years; common comorbidities included peptic ulcer disease, congestive heart failure, and diabetes.
• First-line therapy was predominantly CHOP/CHOP-like regimens; later lines were heterogeneous and shorter. Median monthly cost was $9712, driven by drug and hospitalization expenses.

Conclusions:

• PTCL patients in Japan face a significant clinical and economic burden.
• Treatment heterogeneity and short durations in later therapy lines indicate ongoing challenges.
• There is a need for more effective, tolerable, and cost-effective treatments for PTCL in Japan.